Showing 101 - 120 results of 75,574 for search '(( 5 ((mean decrease) OR (a decrease)) ) OR ((( 10 mg decrease ) OR ( 16 we decrease ))))', query time: 1.10s Refine Results
  1. 101

    Image_2_Decreased Opioid Consumption in Bone Marrow Harvest Patients Using Quadratus Lumborum Blocks in a Standardized Protocol.PDF by Nicole C. McCoy (12459036)

    Published 2022
    “…The implementation group showed significantly reduced median intraoperative (20.0 mg vs. 0.0 mg; p < 0.001) and total opioid consumption (20.5 mg vs. 0.0 mg; p < 0.001). The number of patients who received any opioids decreased from 84.2% (16/19) before implementation to 23.1% (3/13) after implementation.…”
  2. 102

    Image_1_Decreased Opioid Consumption in Bone Marrow Harvest Patients Using Quadratus Lumborum Blocks in a Standardized Protocol.PDF by Nicole C. McCoy (12459036)

    Published 2022
    “…The implementation group showed significantly reduced median intraoperative (20.0 mg vs. 0.0 mg; p < 0.001) and total opioid consumption (20.5 mg vs. 0.0 mg; p < 0.001). The number of patients who received any opioids decreased from 84.2% (16/19) before implementation to 23.1% (3/13) after implementation.…”
  3. 103

    Image_3_Decreased Opioid Consumption in Bone Marrow Harvest Patients Using Quadratus Lumborum Blocks in a Standardized Protocol.PDF by Nicole C. McCoy (12459036)

    Published 2022
    “…The implementation group showed significantly reduced median intraoperative (20.0 mg vs. 0.0 mg; p < 0.001) and total opioid consumption (20.5 mg vs. 0.0 mg; p < 0.001). The number of patients who received any opioids decreased from 84.2% (16/19) before implementation to 23.1% (3/13) after implementation.…”
  4. 104
  5. 105
  6. 106
  7. 107

    The decrease in lactate induced by pyruvate is blocked by inhibition of MAS and of the TCA cycle in HKI/HKII double KD cells. by Scott John (228011)

    Published 2023
    “…Phase 2a1 evoked by pyruvate had a mean amplitude of 36.00±1.16 (n = 91). …”
  8. 108

    Image_3_Chemical Similarity of Co-occurring Trees Decreases With Precipitation and Temperature in North American Forests.jpg by Brian E. Sedio (10875330)

    Published 2021
    “…To test this prediction, we compared patterns of chemical and morphological trait diversity of 140 woody plant species among seven temperate forests in North America representing 16.2°C variation in mean annual temperature (MAT), 2,115 mm variation in mean annual precipitation (MAP), and from 10 to 68 co-occurring species. …”
  9. 109

    Image_2_Chemical Similarity of Co-occurring Trees Decreases With Precipitation and Temperature in North American Forests.jpg by Brian E. Sedio (10875330)

    Published 2021
    “…To test this prediction, we compared patterns of chemical and morphological trait diversity of 140 woody plant species among seven temperate forests in North America representing 16.2°C variation in mean annual temperature (MAT), 2,115 mm variation in mean annual precipitation (MAP), and from 10 to 68 co-occurring species. …”
  10. 110

    Image_1_Chemical Similarity of Co-occurring Trees Decreases With Precipitation and Temperature in North American Forests.jpg by Brian E. Sedio (10875330)

    Published 2021
    “…To test this prediction, we compared patterns of chemical and morphological trait diversity of 140 woody plant species among seven temperate forests in North America representing 16.2°C variation in mean annual temperature (MAT), 2,115 mm variation in mean annual precipitation (MAP), and from 10 to 68 co-occurring species. …”
  11. 111

    Image_4_Chemical Similarity of Co-occurring Trees Decreases With Precipitation and Temperature in North American Forests.jpg by Brian E. Sedio (10875330)

    Published 2021
    “…To test this prediction, we compared patterns of chemical and morphological trait diversity of 140 woody plant species among seven temperate forests in North America representing 16.2°C variation in mean annual temperature (MAT), 2,115 mm variation in mean annual precipitation (MAP), and from 10 to 68 co-occurring species. …”
  12. 112
  13. 113
  14. 114

    DAF-16/FOXO is Required for Locomotory Healthspan and Lifespan Benefits of Genetic Glycolysis Disruption. by Brian Onken (86790)

    Published 2020
    “…WT later in life [<a href="http://www.plosgenetics.org/article/info:doi/10.1371/journal.pgen.1008982#pgen.1008982.ref091" target="_blank">91</a>, <a href="http://www.plosgenetics.org/article/info:doi/10.1371/journal.pgen.1008982#pgen.1008982.ref092" target="_blank">92</a>]; we note that, although comparison of scores across experiments is not possible due to variation in baseline values, the swimming rate of <i>daf-16(mgDf50)</i> control animals was slightly lower than WT controls on the same day of life (in <a href="http://www.plosgenetics.org/article/info:doi/10.1371/journal.pgen.1008982#pgen.1008982.g001" target="_blank">Fig 1C</a>; mean of 46.17 head thrashes/30 sec. for <i>daf-16</i> vs. 52.17 head thrashes/30 sec. for WT on day 10). …”
  15. 115
  16. 116

    Lipid profile is associated with decreased fatigue in individuals with progressive multiple sclerosis following a diet-based intervention: Results from a pilot study by Kelly Fellows Maxwell (6852752)

    Published 2019
    “…At 12 months, increases in HDL-C (mean change: +6.0 mg/dl; 95% CI: 0.3, 12.0; p = 0.049) and decreases in BMI (mean change: -2.6 kg/m<sup>2</sup>; 95% CI: -3.6, -2.5; p < 0.001), LDL-C (mean change: -10.4 mg/dl; 95% CI:-19.7, -1.2; p = 0.029), TG (mean change: -29.2 mg/dl; 95% CI: -44.3, -14.2; p = 0.001), TG to HDL-C ratio (mean change: -0.6; 95% CI: -1.0, -0.3; p = 0.002) and TC to HDL-C ratio (mean change:-0.6; 95% CI: -1.0, -0.3; p = 0.003) were observed compared to baseline. …”
  17. 117
  18. 118
  19. 119

    Mean SARS-CoV-2 viral load log 10 between groups. by Bruno Martins Tomazini (6509528)

    Published 2024
    “…</p><p>Results</p><p>From September 25, 2021, to February 3, 2022, 153 patients were randomized. The mean decay rate in SARS-CoV-2 viral load log<sub>10</sub> within 10 days was -3.75 (95% CI, -4.11; -3.19) in the placebo group, -3.83 (95% CI, -4.40; -2.27) in the halofuginone 0.5mg group and -4.13 (95% CI, -4.69; -3.57) in the halofuginone 1mg group, with no statistically significant difference in between placebo vs. halofuginone 0.5mg (mean difference -0.08; 95% CI -0.82 to 0.66, p = 0.96) and between placebo vs. halofuginone 1mg (mean difference -0.38; 95% CI, -1.11; 0.36, p = 0.41). …”
  20. 120